Stoke Therapeutics (STOK) EBITDA (2018 - 2026)

Stoke Therapeutics' EBITDA history runs 9 years deep, the most recent figure standing at -$53.4 million for Q1 2026.

• In Q1 2026, EBITDA fell 148.02% year-over-year to -$53.4 million; the TTM figure through Mar 2026 stood at -$185.2 million (down 584.41% YoY), while the FY2025 annual figure was -$20.6 million, up 79.69% from the prior year.
• EBITDA for Q1 2026 stood at -$53.4 million, up from -$61.4 million in the prior quarter.
• The five-year high for EBITDA was $111.2 million in Q1 2025, with the low at -$61.4 million in Q4 2025.
• The 5-year median for EBITDA is -$27.3 million (2025), against an average of -$23.2 million.
• Peak annual rise in EBITDA reached 492.08% in 2025, while the deepest fall reached 350.0% in 2025.
• Stoke Therapeutics' EBITDA stood at -$27.2 million in 2022, then slipped by 8.87% to -$29.6 million in 2023, then soared by 53.85% to -$13.7 million in 2024, then tumbled by 350.0% to -$61.4 million in 2025, then climbed by 13.06% to -$53.4 million in 2026.
• Business Quant data shows STOK's EBITDA at -$53.4 million in Q1 2026, -$61.4 million in Q4 2025, and -$43.1 million in Q3 2025.